Dediabetes Logo
Preguntas
Respuestas publicadas conectadas con evidencia
Referencia clínica
Dossieres detallados de intervenciones y resultados
Investigacion reciente
Estudios mas recientes
Acerca de
Cómo funciona deDiabetes
Configuracion
Entrar / Unirse
Resumen de Investigación
Analyzed using Evidence Intelligence™

Efsubaglutide improves diabetes control with metformin

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

Última actualización 12 de septiembre de 2026

Key finding

HbA1c decreased by 1.43% with 3 mg (p < 0.0001).

Efsubaglutide alfa significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metformin.

Quick read

Study at a glance

The essential study design details in one scan.

EvidenceScore™

Moderate

Study type

RCTs

Follow-up

Medium-Term (3–12 mo)

Risk of bias

Some Concerns

Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.

Plain-language summary

What this paper says

A plain-language read of the study’s main message and where it applies.

Study focus

Efsubaglutide alfa significantly improved glycaemic control in adults with type 2 diabetes inadequately controlled on metformin.

Clinical relevance

These findings are significant as they suggest that efsubaglutide could be a valuable addition to the treatment options for adults with type 2 diabetes who are not achieving adequate glycaemic control with metformin alone. Improved glycaemic control can lead to better long-term health outcomes and reduce the risk of diabetes-related complications.

Keep in mind

The study's population may not be representative of all adults with type 2 diabetes. The duration of the study may not capture long-term effects. Potential biases in self-reported data on weight and glycaemic control.

Published in

Referencia de la Revista

Publication details and source links for this paper.

Weiping J, Fei G, Jingyi L, et al. Efsubaglutide alfa improves glycaemic control in adults with type 2 diabetes inadequately controlled on metformin. Nature Communications. 2026;17:6222. doi:10.1038/s41467-026-72574-7

View DOIView on PubMedView on PMC

Efectos Principales

HbA1c decreased by 1.43% with efsubaglutide (p < 0.0001).

Fasting plasma glucose decreased by 2.42 mmol/L with efsubaglutide (p < 0.001).

Body weight decreased by 2.74 kg with efsubaglutide (p < 0.001).

Evidence network

How this study fits

Understand where this research contributes within the broader evidence network.

Evidence Context

This study contributes evidence to Efsubaglutide 3 mg and Body weight, Fasting Plasma Glucose (FPG), HbA1c.

This study contributes evidence to

Intervention

Efsubaglutide 3 mg

Outcome

Body weight

Evidence topic

Fasting Blood Glucose

Primary intervention

Efsubaglutide 3 mg

Primary outcomes

  • Body weight
  • Fasting Plasma Glucose (FPG)
  • HbA1c

Evidence topics

Fasting Blood GlucoseGlycemic ControlHbA1c ReductionWeight Loss

Primary intervention

Efsubaglutide 3 mg

Primary outcomes

Body weightFasting Plasma Glucose (FPG)HbA1c

Evidence relationships

Intervention and outcome relationships this study adds to the evidence network.

3
Evidence pairs
3
Relationships
4
Evidence topics
contributes_evidence

Editorial context

Why this study matters

See why this paper is useful beyond its individual results.

Evidence network role

This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.

Moderate contributionModerate confidenceNetwork score: 72

4

Related topics

3

Evidence pairs

1865

Related studies

High relevance in at least one topic

Why it is useful

  • Contributes to 3 evidence relationships
  • Includes primary outcome data
  • Linked to 4 direct semantic evidence topics

Topic contributions

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Evidence topic

Contributes evidence

Agrega evidencia relacionada a tu Evidence Tracker

Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.

Evidencia principal

Tema de evidencia

Fasting Blood Glucose

matched_outcome

Evidencia relacionada

Tema de evidencia

Glycemic Control

Guardar evidencia

Core evidence

Study findings

The primary outcomes reported in this study.

Body weight

Efsubaglutide 3 mg → Body weight

Efsubaglutide 3 mg → Body weight

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

Fasting Plasma Glucose (FPG)

Efsubaglutide 3 mg → Fasting Plasma Glucose (FPG)

Efsubaglutide 3 mg → Fasting Plasma Glucose (FPG)

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

HbA1c

Efsubaglutide 3 mg → HbA1c

Efsubaglutide 3 mg → HbA1c

Evidence Intelligence™
EvidenceScore™
Emerging
Score 59 · Based on 1 study
ImpactScore™
100
Very Positive
ConsistencyScore™
unclear
Not enough independent studies
Estudios de apoyo: Basado en 1 estudio
Add to Evidence Tracker

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

evidence suggest

La Evidencia Sugiere

  • Efsubaglutide reduced HbA1c by 1.43%, significantly more than placebo.
  • Fasting plasma glucose decreased by 2.42 mmol/L with efsubaglutide.
  • Body weight decreased by 2.74 kg in the efsubaglutide group.
who this applies

A quién se aplica

  • Adults with type 2 diabetes inadequately controlled on metformin.
  • Individuals seeking additional treatment options for glycaemic control.
keep in mind

Tener en Cuenta

  • Results may not apply to individuals not on metformin.
  • Further studies are needed to assess long-term safety and efficacy.
  • The study's findings are based on a specific population and may not generalize.
between the lines

Entre Líneas

  • The study's population may not be representative of all adults with type 2 diabetes.
  • The duration of the study may not capture long-term effects.
  • Potential biases in self-reported data on weight and glycaemic control.

Evidence Library

Build your evidence library

Save research, organize studies, and quickly find important evidence again.

Connected Evidence

Explore related studies, evidence collections, and research questions.

Relationships organized using the Dediabetes Evidence Intelligence™ framework.

Desarrollado con el marco Evidence Intelligence™ de Dediabetes

This study contributes to evidence on Efsubaglutide 3 mg and Body Weight, Efsubaglutide 3 mg and Fasting Glucose.

Relaciones de evidencia relacionadas

Explore in Evidence Explorer

This study contributes to the evidence on the following intervention-outcome relationships.

Questions answered by this study

Generated from the study's connected evidence using Evidence Intelligence™.

Does Efsubaglutide 3 mg affect body weight?

Emerging Evidence

Efsubaglutide 3 mg appears to affect body weight.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Body weight

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence

Does Efsubaglutide 3 mg improve fasting plasma glucose (FPG)?

Emerging Evidence

Efsubaglutide 3 mg appears to improve fasting plasma glucose (FPG).

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    Fasting Plasma Glucose (FPG)

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence

Does Efsubaglutide 3 mg lower HbA1c?

Emerging Evidence

Efsubaglutide 3 mg appears to lower HbA1c.

ConsistencyScore™: Consistency cannot yet be determined from the available evidence.

Ranked evidence signals

  1. 1

    HbA1c

    EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study

Why this answer: This answer is based on a single supporting study.

Limitations

  • Only one supporting study is available.
1 supporting study
View Full Evidence
Learn how Evidence Intelligence™ works

Next steps

Continue your research

Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.

Evidence topics

Follow the topics this study contributes to.

Fasting Blood Glucose Evidence HubGlycemic Control Evidence HubHbA1c Reduction Evidence HubWeight Loss Evidence Hub

Explore in Evidence Explorer

Open broader Evidence Explorer views for this relationship.

All studies on Efsubaglutide 3 mg and Body weightAll studies on Efsubaglutide 3 mg and Fasting Plasma Glucose (FPG)All studies on Efsubaglutide 3 mg and HbA1c

Related research

Read related research summaries.

Insulin glargine plus metformin and glimepiride improves glycemic control in type 2 diabetes.Exercise Improves Serum Albumin Levels in Women with Type 2 DiabetesHRS-7535 improves glycemic control in adults with type 2 diabetesBariatric surgery improves glucose homeostasis in type 2 diabetes.CT-868 Improves Glycaemic Control in Type 2 Diabetes

Sin anuncios. Sin rastreo.

Centrada en la evidencia, no en la publicidad.

Segura y privada

Tus datos siempre están protegidos.

Siempre al día

Se agregan nuevos estudios todos los días.